|57.73||-0.7700||-1.32%||Vol 873.27K||1Y Perf 53.62%|
|May 19th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||66.75||Analyst Rating||Strong Buy 1.50|
|Potential %||15.62||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 54.64|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||78.01||Earnings Rating||Neutral|
|Market Cap||5.45B||Earnings Date||10th May 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.93|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||905.36K|
|Avg. Monthly Volume||998.83K|
|Avg. Quarterly Volume||943.29K|
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) stock closed at 57.73 per share at the end of the most recent trading day (a -1.32% change compared to the prior day closing price) with a volume of 873.27K shares and market capitalization of 5.45B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 383 people. Intra-Cellular Therapies Inc. CEO is Sharon Mates.
The one-year performance of Intra-Cellular Therapies Inc. stock is 53.62%, while year-to-date (YTD) performance is 10.3%. ITCI stock has a five-year performance of 440.04%. Its 52-week range is between 28.4 and 66, which gives ITCI stock a 52-week price range ratio of 78.01%
Intra-Cellular Therapies Inc. currently has a PE ratio of -16.20, a price-to-book (PB) ratio of 7.03, a price-to-sale (PS) ratio of 55.09, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.32%, a ROC of -41.78% and a ROE of -44.28%. The company’s profit margin is -%, its EBITDA margin is -301.90%, and its revenue ttm is $100.88 Million , which makes it $1.07 revenue per share.
Of the last four earnings reports from Intra-Cellular Therapies Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.93 for the next earnings report. Intra-Cellular Therapies Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Intra-Cellular Therapies Inc. is Strong Buy (1.5), with a target price of $66.75, which is +15.62% compared to the current price. The earnings rating for Intra-Cellular Therapies Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Intra-Cellular Therapies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Intra-Cellular Therapies Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.56, ATR14 : 3.31, CCI20 : 112.37, Chaikin Money Flow : -0.04, MACD : 0.01, Money Flow Index : 61.79, ROC : 13.00, RSI : 56.45, STOCH (14,3) : 91.16, STOCH RSI : 0.80, UO : 64.98, Williams %R : -8.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Intra-Cellular Therapies Inc. in the last 12-months were: Christopher Alafi (Sold 75 000 shares of value $3 017 236 ), Joel S. Marcus (Option Excercise at a value of $0), Joel S. Marcus (Sold 20 000 shares of value $1 062 750 ), Lawrence J. Hineline (Option Excercise at a value of $2 941 950), Lawrence J. Hineline (Sold 205 082 shares of value $9 707 589 ), Mark Neumann (Option Excercise at a value of $1 099 210), Mark Neumann (Sold 131 883 shares of value $7 577 683 ), Michael I. Halstead (Option Excercise at a value of $2 897 493), Michael I. Halstead (Sold 207 641 shares of value $9 830 151 ), Rory B. Riggs (Option Excercise at a value of $0), Sharon Mates (Option Excercise at a value of $142 000), Sharon Mates (Sold 119 743 shares of value $5 250 841 ), Suresh K. Durgam (Option Excercise at a value of $0), Suresh K. Durgam (Sold 25 307 shares of value $1 224 844 )
Fri, 08 Apr 2022 01:49 GMT RBC Capital Believes Intra-Cellular Therapies (ITCI) Wont Stop Here- TipRanks. All rights reserved.
Wed, 02 Mar 2022 13:45 GMT Jefferies Believes Intra-Cellular Therapies (ITCI) Still Has Room to Grow- TipRanks. All rights reserved.
Mon, 28 Feb 2022 13:35 GMT Intra-Cellular Therapies (ITCI) Received its Third Buy in a Row- TipRanks. All rights reserved.
Fri, 11 Feb 2022 01:55 GMT RBC Capital Believes Intra-Cellular Therapies (ITCI) Still Has Room to Grow- TipRanks. All rights reserved.
Fri, 07 Jan 2022 01:51 GMT Intra-Cellular Therapies (ITCI) Receives a Buy from RBC Capital- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.